Fuchs S, Baffour R, Zhou Y F, Shou M, Pierre A, Tio F O, Weissman N J, Leon M B, Epstein S E, Kornowski R
Cardiovascular Research Institute, Washington Hospital Center, Washington, DC 20010, USA.
J Am Coll Cardiol. 2001 May;37(6):1726-32. doi: 10.1016/s0735-1097(01)01200-1.
We tested the hypothesis that intramyocardial injection of autologous bone marrow (ABM) promotes collateral development in ischemic porcine myocardium. We also defined, in vitro, whether bone marrow (BM) cells secrete vascular endothelial growth factor (VEGF) and macrophage chemoattractant protein-1 (MCP-1).
The natural processes leading to collateral development are extremely complex, requiring multiple growth factors interacting in concert and in sequence. Because optimal angiogenesis may, therefore, require multiple angiogenic factors, we thought that injection of BM, which contains cells that secrete numerous angiogenic factors, might provide optimal therapeutic angiogenesis.
Bone marrow was cultured four weeks in vitro. Conditioned medium was assayed for VEGF and MCP-1 and was added to cultured pig aortic endothelial cells (PAEC) to assess proliferation. Four weeks after left circumflex ameroid implantation, freshly aspirated ABM (n = 7) or heparinized saline (n = 7) was injected transendocardially into the ischemic zone (0.2 ml/injection at 12 sites). Echocardiography to assess myocardial thickening and microspheres to assess perfusion were performed at rest and during stress.
Vascular endothelial growth factor and MCP-1 concentrations increased in a time-related manner. The conditioned medium enhanced, in a dose-related manner, PAEC proliferation. Collateral flow (ischemic/normal zone X 100) improved in ABM-treated pigs (ABM: 98 +/- 14 vs. 83 +/- 12 at rest, p = 0.001; 89 +/- 18 vs. 78 +/- 12 during adenosine, p = 0.025; controls: 92 +/- 10 vs. 89 +/- 9 at rest, p = 0.49; 78 +/- 11 vs. 77 +/- 5 during adenosine, p = 0.75). Similarly, contractility increased in ABM-treated pigs (ABM: 83 +/- 21 vs. 60 +/- 32 at rest, p = 0.04; 91 +/- 44 vs. 36 +/- 43 during pacing, p = 0.056; controls: 69 +/- 48 vs. 64 +/- 46 at rest, p = 0.74; 65 +/- 56 vs. 37 +/- 56 during pacing, p = 0.23).
Bone marrow cells secrete angiogenic factors that induce endothelial cell proliferation and, when injected transendocardially, augment collateral perfusion and myocardial function in ischemic myocardium.
我们验证了心肌内注射自体骨髓(ABM)可促进缺血猪心肌侧支血管发育的假说。我们还在体外确定了骨髓(BM)细胞是否分泌血管内皮生长因子(VEGF)和巨噬细胞趋化蛋白-1(MCP-1)。
导致侧支血管发育的自然过程极其复杂,需要多种生长因子协同且按顺序相互作用。因此,由于最佳的血管生成可能需要多种血管生成因子,我们认为注射含有能分泌多种血管生成因子细胞的BM,可能会提供最佳的治疗性血管生成。
骨髓在体外培养4周。检测条件培养基中的VEGF和MCP-1,并将其添加到培养的猪主动脉内皮细胞(PAEC)中以评估增殖情况。在左回旋支植入阿梅氏环4周后,将新鲜抽取的ABM(n = 7)或肝素化盐水(n = 7)经心内膜注射到缺血区(12个部位,每次注射0.2 ml)。在静息和应激状态下进行超声心动图检查以评估心肌增厚情况,并使用微球评估灌注情况。
VEGF和MCP-1浓度呈时间依赖性增加。条件培养基以剂量依赖性方式增强PAEC增殖。ABM治疗组猪的侧支血流(缺血区/正常区×100)得到改善(ABM组:静息时98±14比83±12,p = 0.001;腺苷激发时89±18比78±12,p = 0.025;对照组:静息时92±10比89±9,p = 0.49;腺苷激发时78±11比77±5,p = 0.75)。同样,ABM治疗组猪的心肌收缩力增强(ABM组:静息时83±21比60±32,p = 0.04;起搏时91±44比36±43,p = 0.056;对照组:静息时69±48比64±46,p = 0.74;起搏时65±56比37±56,p = 0.23)。
骨髓细胞分泌血管生成因子,可诱导内皮细胞增殖,经心内膜注射后可增加缺血心肌的侧支灌注和心肌功能。